# Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

> **NCT00210743** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 67 (actual)

## Conditions studied

- Anemia
- Kidney Diseases

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00210743
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2011-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210743, "Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00210743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*